# Marco Tucci

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 99 papers | 6,809 citations | 32 h-index | 82 g-index |
| 104 ext. papers | 8,016 ext. citations | 5.3 avg, IF | 5.14 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 99 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222 | 10.2 | 3838 |
| 98 | Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. *Therapeutic Advances in Medical Oncology*, **2018**, 10, 1758835918794630 | 5.4 | 202 |
| 97 | Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. *Arthritis and Rheumatism*, **2008**, 58, 251-62 | | 169 |
| 96 | Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. *Annals of Oncology*, **2014**, 25, 1404-1410 | 10.3 | 114 |
| 95 | Immune system and melanoma biology: a balance between immunosurveillance and immune escape. *Oncotarget*, **2017**, 8, 106132-106142 | 3.3 | 109 |
| 94 | Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. *Arthritis and Rheumatism*, **2004**, 50, 1842-9 | | 104 |
| 93 | Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. *Clinical and Experimental Immunology*, **2004**, 138, 171-8 | 6.2 | 100 |
| 92 | Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. *Blood*, **2002**, 99, 1305-13 | 2.2 | 90 |
| 91 | Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. *Aids*, **1996**, 10, 131-41 | 3.5 | 83 |
| 90 | Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. *Clinical and Experimental Immunology*, **2008**, 154, 247-54 | 6.2 | 80 |
| 89 | Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker. *Journal of Translational Medicine*, **2015**, 13, P14 | 8.5 | 78 |
| 88 | Urinary biomarkers in lupus nephritis. *Autoimmunity Reviews*, **2006**, 5, 383-8 | 13.6 | 77 |
| 87 | Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. *Oncotarget*, **2018**, 9, 20826-20837 | 3.3 | 74 |
| 86 | Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. *British Journal of Haematology*, **2003**, 122, 39-52 | 4.5 | 60 |
| 85 | Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. *Autoimmunity Reviews*, **2005**, 4, 542-8 | 13.6 | 57 |
| 84 | Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. *OncoImmunology*, **2018**, 7, e1387706 | 7.2 | 56 |
| 83 | Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. *Journal of Immunology*, **2005**, 175, 4777-82 | 5.3 | 56 |

| | | | |
|---|---|---|---|
| 82 | Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. *Cancer Treatment Reviews*, **2015**, 41, 798-808 | 14.4 | 55 |
| 81 | Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. *Frontiers in Oncology*, **2019**, 9, 1148 | 5.3 | 52 |
| 80 | The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. *Neuroendocrinology*, **2019**, 109, 83-99 | 5.6 | 48 |
| 79 | Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice **2020**, 8, | | 47 |
| 78 | Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. *Clinical and Experimental Immunology*, **2006**, 146, 21-31 | 6.2 | 46 |
| 77 | Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. *Blood*, **2001**, 97, 1155-64 | 2.2 | 46 |
| 76 | The immune escape in melanoma: role of the impaired dendritic cell function. *Expert Review of Clinical Immunology*, **2014**, 10, 1395-404 | 5.1 | 42 |
| 75 | PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression. *Journal of Bone and Mineral Research*, **2014**, 29, 55-66 | 6.3 | 42 |
| 74 | Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus. *Journal of Biomedicine and Biotechnology*, **2010**, 2010, 457146 | | 41 |
| 73 | In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. *British Journal of Haematology*, **2012**, 157, 586-98 | 4.5 | 40 |
| 72 | Antiphosphatidylserine antibodies in human immunodeficiency virus-1 patients with evidence of T-cell apoptosis and mediate antibody- dependent cellular cytotoxicity [see comments]. *Blood*, **1996**, 87, 5185-5195 | 2.2 | 40 |
| 71 | The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. *Annals of the New York Academy of Sciences*, **2005**, 1051, 421-32 | 6.5 | 38 |
| 70 | miRNAs in melanoma: a defined role in tumor progression and metastasis. *Expert Review of Clinical Immunology*, **2016**, 12, 79-89 | 5.1 | 35 |
| 69 | Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation. *British Journal of Haematology*, **2013**, 161, 821-31 | 4.5 | 35 |
| 68 | Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?. *Oncologist*, **2011**, 16, 1040-8 | 5.7 | 35 |
| 67 | The density and spatial tissue distribution of CD8 and CD163 immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors **2019**, 7, 308 | | 32 |
| 66 | Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro. *Experimental Hematology*, **2011**, 39, 773-83.e1 | 3.1 | 32 |
| 65 | Avβ integrin: Pathogenetic role in osteotropic tumors. *Critical Reviews in Oncology/Hematology*, **2015**, 96, 183-93 | 7 | 29 |

| | | | |
|---|---|---|---|
| 64 | Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis. *Journal of Translational Medicine*, **2019**, 17, 230 | 8.5 | 29 |
| 63 | Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. *Journal of Hypertension*, **2006**, 24, 1307-18 | 1.9 | 29 |
| 62 | beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. *Cancer Research*, **2009**, 69, 6738-46 | 10.1 | 28 |
| 61 | Non-Melanoma Skin Cancers: Biological and Clinical Features. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 28 |
| 60 | Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. *European Journal of Cancer*, **2021**, 142, 18-28 | 7.5 | 27 |
| 59 | Does cilengitide deserve another chance?. *Lancet Oncology, The*, **2014**, 15, e584-e585 | 21.7 | 26 |
| 58 | Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. *Lupus*, **2003**, 12, 8-14 | 2.6 | 26 |
| 57 | Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. *PLoS ONE*, **2014**, 9, e105268 | 3.7 | 25 |
| 56 | Revisiting the Role of Exosomes in Colorectal Cancer:. *Frontiers in Oncology*, **2019**, 9, 521 | 5.3 | 24 |
| 55 | Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?. *Oncologist*, **2009**, 14, 264-75 | 5.7 | 24 |
| 54 | Oversecretion of cytokines and chemokines in lupus nephritis is regulated by intraparenchymal dendritic cells: a review. *Annals of the New York Academy of Sciences*, **2009**, 1173, 449-57 | 6.5 | 22 |
| 53 | Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression. *International Journal of Molecular Sciences*, **2019**, 21, | 6.3 | 22 |
| 52 | Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. *Clinical and Experimental Medicine*, **2019**, 19, 1-21 | 4.9 | 22 |
| 51 | SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. *Oncotarget*, **2018**, 9, 25355-25382 | 3.3 | 22 |
| 50 | Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. *European Journal of Cancer*, **2020**, 134, 19-28 | 7.5 | 21 |
| 49 | Increased IL-18 production by dendritic cells in active inflammatory myopathies. *Annals of the New York Academy of Sciences*, **2007**, 1107, 184-92 | 6.5 | 20 |
| 48 | The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine. *Tumor Biology*, **2019**, 42, 1010428319837138 | 2.9 | 18 |
| 47 | Sjögren's syndrome: an autoimmune disorder with otolaryngological involvement. *Acta Otorhinolaryngologica Italica*, **2005**, 25, 139-44 | 2.8 | 18 |

| | | | |
|---|---|---|---|
| 46 | Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. *Cancer Treatment Reviews*, **2018**, 69, 21-28 | 14.4 | 18 |
| 45 | Role of active drug transporters in refractory multiple myeloma. *Current Topics in Medicinal Chemistry*, **2009**, 9, 218-24 | 3 | 17 |
| 44 | Recent advances in understanding the pathogenesis of anemia in multiple myeloma. *International Journal of Hematology*, **2003**, 78, 121-5 | 2.3 | 17 |
| 43 | Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. *Clinical Sarcoma Research*, **2013**, 3, 6 | 2.5 | 16 |
| 42 | Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. *BMC Cancer*, **2015**, 15, 692 | 4.8 | 15 |
| 41 | A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression. *Stem Cells and Development*, **2015**, 24, 1457-70 | 4.4 | 14 |
| 40 | Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. *Scientific Reports*, **2019**, 9, 17276 | 4.9 | 12 |
| 39 | Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. *BMC Cancer*, **2016**, 16, 87 | 4.8 | 11 |
| 38 | The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919875549 | 5.4 | 10 |
| 37 | Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. *International Journal of Clinical and Laboratory Research*, **1998**, 28, 215-25 | | 10 |
| 36 | No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. *Cancers*, **2021**, 13, | 6.6 | 10 |
| 35 | An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. *Experimental Hematology*, **2014**, 42, 897-908.e1 | 3.1 | 9 |
| 34 | Anemia in multiple myeloma: role of deregulated plasma cell apoptosis. *Leukemia and Lymphoma*, **2002**, 43, 1527-33 | 1.9 | 9 |
| 33 | Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and alpha-interferon therapy. *International Journal of Clinical and Laboratory Research*, **1995**, 25, 79-83 | | 9 |
| 32 | Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 8 |
| 31 | Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells. *British Journal of Haematology*, **2016**, 173, 59-69 | 4.5 | 8 |
| 30 | DLC-1 down-regulation via exosomal miR-106b-3p exchange promotes CRC metastasis by the epithelial-to-mesenchymal transition. *Clinical Science*, **2020**, 134, 955-959 | 6.5 | 8 |
| 29 | Large Extracellular Vesicles-A New Frontier of Liquid Biopsy in Oncology. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 8 |

| | | | |
|---|---|---|---|
| 28 | Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease. *Clinical and Experimental Medicine*, **2002**, 2, 13-27 | 4.9 | 7 |
| 27 | VEINCTR-N, an Immunogenic Epitope of Fas (CD95/Apo-I), and Soluble Fas Enhance T-cell Apoptosis in vitro. II. Functional Analysis and Possible Implications in HIV-1 Disease. *Molecular Medicine*, **2000**, 6, 509-526 | 6.2 | 7 |
| 26 | Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma. *Clinical and Translational Oncology*, **2019**, 21, 845-854 | 3.6 | 7 |
| 25 | Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. *Neuroendocrinology*, **2021**, 111, 207-216 | 5.6 | 6 |
| 24 | An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. *Frontiers in Oncology*, **2020**, 10, 1652 | 5.3 | 6 |
| 23 | Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920905415 | 5.4 | 6 |
| 22 | Nef protein induces differential effects in CD8+ cells from HIV-1-infected patients. *European Journal of Clinical Investigation*, **1999**, 29, 980-91 | 4.6 | 5 |
| 21 | Cytotherapies in multiple myeloma: a complementary approach to current treatments?. *Expert Opinion on Biological Therapy*, **2013**, 13 Suppl 1, S23-34 | 5.4 | 4 |
| 20 | Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. *Frontiers in Oncology*, **2020**, 10, 581130 | 5.3 | 4 |
| 19 | The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight. *Cardiovascular Drugs and Therapy*, **2021**, 35, 505-519 | 3.9 | 4 |
| 18 | Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma. *Experimental Hematology*, **2017**, 47, 48-53 | 3.1 | 3 |
| 17 | The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. *Current Treatment Options in Oncology*, **2019**, 20, 72 | 5.4 | 3 |
| 16 | Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. *Cancers*, **2021**, 13, | 6.6 | 3 |
| 15 | The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. *Genes*, **2021**, 12, | 4.2 | 3 |
| 14 | PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. *Journal of Translational Medicine*, **2021**, 19, 270 | 8.5 | 3 |
| 13 | Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. *Journal of Translational Medicine*, **2015**, 13, P15 | 8.5 | 2 |
| 12 | Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer. *Journal of Clinical Oncology*, **2015**, 33, e66-70 | 2.2 | 2 |
| 11 | The Day after Mass COVID-19 Vaccination: Higher Hypermetabolic Lymphadenopathy Detection on PET/CT and Impact on Oncologic Patients Management. *Cancers*, **2021**, 13, | 6.6 | 2 |

| | | | |
|---|---|---|---|
| 10 | Primary intimal sarcoma of the thoracic aorta. *Journal of Experimental and Clinical Cancer Research*, **2005**, 24, 139-42 | | 2 |
| 9 | AlphaVBeta3 (VB) Integrin Drives the Osteoclastogenesis through a Osteoclast-Like Functional Differentiation of Myeloma Cells.. *Blood*, **2007**, 110, 814-814 | 2.2 | 1 |
| 8 | A Lipidomic Approach to Identify Potential Biomarkers in Exosomes From Melanoma Cells With Different Metastatic Potential. *Frontiers in Physiology*, **2021**, 12, 748895 | 4.6 | 1 |
| 7 | Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). *Targeted Oncology*, **2021**, 16, 789-799 | 5 | 1 |
| 6 | Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. *Human Vaccines and Immunotherapeutics*, **2021**, 1-9 | 4.4 | 1 |
| 5 | Successful treatment with apremilast of severe psoriasis exacerbation during nivolumab therapy for metastatic melanoma. *Dermatologic Therapy*, **2021**, 34, e14653 | 2.2 | 1 |
| 4 | Animal-type melanoma: dog or wolf? A review of the literature and a case report. *Expert Reviews in Molecular Medicine*, **2018**, 20, e5 | 6.7 | 1 |
| 3 | Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.. *Journal of Translational Medicine*, **2022**, 20, 159 | 8.5 | 1 |
| 2 | COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211053416 | 5.4 | 0 |
| 1 | Vascular and Cardiac Prognostic Determinants in Patients with Gynecological Cancers: A Six-Year Follow-up Study. *Applied Sciences (Switzerland)*, **2021**, 11, 6091 | 2.6 | 0 |